Advertisement

Anti-EpCAM Antibody-Drug Conjugate Shows High Activity against Pancreatic Cancer


Advertisement
Get Permission

Human epithelial cell adhesion molecule (EpCAM) is overexpressed in many cancers. Although anti-EpCAM antibodies have shown promise in preclinical studies, early-phase clinical evaluation of these antibodies has been disappointing.

To determine whether the antitumor activity of anti-EpCAM antibody could be improved, Moldenhauer and colleagues from the German Cancer Research Center in Heidelberg, Germany, constructed a novel conjugate consisting of a chimerized anti-EpCAM monoclonal antibody and α-amanitin, a toxin that inhibits DNA transcription. The conjugate reduced cell proliferation in human pancreatic, colorectal, breast, and bile duct cancer cell lines.

A single dose of the conjugate significantly reduced subcutaneous pancreatic carcinoma xenograft growth in immunocompromised mice compared with the antibody alone. At higher doses of α-amanitin in the conjugate, complete tumor regression was seen in 90% of tumors, with increased apoptosis and reduced cell proliferation observed in all animals.

As stated by the investigators, these findings suggest that “anti-EpCAM antibody conjugates with α-amanitin have the potential to be highly effective therapeutic agents for pancreatic carcinomas and various EpCAM-expressing malignancies.” ■

Moldenhauer G, et al: J Natl Cancer Inst 104:622-634, 2012.


Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.